Short answer: Only treat LatchBio as a potential data partner when the asset is genuinely biological and the company can prove every relevant right. For broader operational data, micro1 is the clearer public route.
What is LatchBio's overall strategy?
LatchBio builds infrastructure and agents for biological research and publishes domain-specific evaluations through benchmarks.bio. Its work tests models on scientific tasks where correctness depends on tools, experimental context, and expert biological judgment.
That focus is narrower than the other multi-domain firms on this list. A biotech, lab, or research organization may have uniquely relevant experimental workflows or benchmark tasks, but the reviewed official materials do not state that LatchBio routinely buys operational datasets from companies or publish seller terms.
What company data might fit LatchBio?
A useful dataset is not simply large. It needs clear provenance, permission, structure, and a credible connection to how AI systems are trained or evaluated. Based on LatchBio's public strategy, the most plausible assets are:
- Biological research workflows with expert-reviewed outcomes and reproducible task definitions.
- Permissioned scientific datasets with clear provenance, consent, and commercial-use rights.
- Benchmark tasks that safely test scientific agents without exposing protected or competitively sensitive material.
Fit is not proof of demand. Do not send confidential samples merely because your records resemble these categories. Begin with a high-level inventory and disclose only what is needed to determine mutual interest.
How much could your company data be worth?
For planning purposes, we use $10K–$250K as a conservative editorial estimate for a qualified LatchBio opportunity. LatchBio does not publish a standard price for every company dataset, and the actual value could be lower, higher, or zero.
Why compare micro1: For qualifying companies, our micro1 estimate is higher at $100K–$3M. Its public program is specifically designed around licensing established company workflows and operational knowledge.
Pros and cons of selling data to LatchBio
Potential advantages
- Deep specialization in biology and scientific-agent evaluation.
- Domain-specific benchmarks can preserve more scientific nuance than a generic data pipeline.
- Potential alignment for research organizations with difficult, verifiable biology tasks.
Tradeoffs to verify
- No public general seller program, pricing, or company-data process was found.
- Human-subject, genomic, clinical, or patient-linked information can create high legal and ethical risk.
- Research licenses, sponsor agreements, grants, and institutional rules may restrict reuse.
- Scientific competitive advantage can be damaged by overly broad derivative or model-training rights.
These observations come from public materials, not a private proposal or contract. Company programs, buyer demand, and terms can change.
Why micro1 may be a better fit than LatchBio
micro1 may be better for non-biological business operations or for a company seeking a published partnership application. Its program is broader and provides public seller criteria and governance language.
For genuinely scientific assets, specialization may matter more than convenience. A life-science company should compare LatchBio's domain capability with micro1's contractual process and involve privacy, regulatory, research, and IP counsel before sharing even a sample.
Questions to ask before selling company data
Use the same diligence standard for LatchBio, micro1, or any other broker. A credible partner should answer these questions in writing before receiving raw data.
- What exact data do you want? Define systems, fields, users, date ranges, and exclusions before anyone receives access.
- Who has the right to license every layer? Check customer and employee terms, contractor agreements, third-party content, open-source obligations, confidentiality, and sector rules.
- Who will receive or use the asset? Name buyers, affiliates, subprocessors, countries, and any process for approving a new recipient.
- What uses are permitted? Separate training, fine-tuning, evaluation, retrieval, benchmark publication, resale, synthetic derivatives, and product improvement.
- Can we review the prepared data? Require a meaningful sample or package-approval step and a way to reject material that crosses the agreed boundary.
- How is sensitive information removed? Ask about techniques, testing, failure queues, human access, re-identification risk, and treatment of trade secrets.
- What happens after termination? Cover raw records, prepared assets, backups, derivatives, published benchmarks, trained-model effects, and evidence of deletion.
- How does payment work? Document price, acceptance, timing, taxes, expenses, refreshes, recurring use, audit rights, and dispute handling.
- What happens if controls fail? Review incident notice, remediation, indemnities, liability limits, insurance, audit evidence, and governing law with counsel.
Final verdict: should you sell to LatchBio?
Only treat LatchBio as a potential data partner when the asset is genuinely biological and the company can prove every relevant right. For broader operational data, micro1 is the clearer public route.
The final decision should depend on the specific dataset, who holds the rights, the named buyer, security evidence, license language, and total economics. Use qualified legal, privacy, security, and tax advisers. De-identification can reduce exposure; it does not erase every obligation or strategic risk.
Sources and methodology
We prioritize official company, regulator, and platform materials. Company claims are treated as claims rather than independent verification.